Celsion Signs Agreement With Fast Track Systems15 February 2006
Fast Track Systems, Inc.,a leading provider of clinical trial data and software designed to reducethe cost and improve productivity within clinical trial operations, todayannounced that CELSION CORPORATION (AMEX: CLN) has selected TrialSpace™Grants Manager® and CROCAS PBT® for its global clinical trial planningand budgeting activities. Dr. William Hahne, Celsion's Vice President Clinical Development andMedical Affairs, commented, "Celsion plans to initiate a global multi-sitePhase II/III clinical study to investigate the use of ThermoDox™, anencapsulation of doxorubicin in Celsion's proprietary heat activatedliposome, in combination with Radiofrequency Ablation to treat primaryliver cancer. The Grants Manager and CROCAS databases, which arerepresentative of clinical costs for the global pharmaceutical industry,will be a useful tool in planning, budgeting and controlling the costs ofthis study." Fast Track Systems Vice President of Sales, Frank Cattie remarked, "AsCelsion continues development of the company's first drug ThermoDox™(doxorubicin encapsulated in the company's heat activated liposome) totreat cancer, our data and software will assist our new partner inproactively managing clinical trial costs. We are very pleased to beworking with Celsion as they continue to pursue their research in cancerand to be adding them to our customer list of over 60 global clinical trialsponsor organizations." About Fast Track Systems: Fast Track's products improve productivity, increase compliance, and reducecosts by solving problems associated with the operational aspects ofclinical trial design and execution. TrialSpace Designer® ensuresgreater consistency and transparency in trial design by capturing protocolcontent as reusable data that can be utilized by other clinical systems andleveraged for related purposes. Grants Manager® and CROCAS® draw fromover 25,000 finalized industry protocols, 240,000 negotiated investigatorgrants, and 4,000 CRO contracts to ensure subscribers understand the truecost and compliance consequences when negotiating clinical agreements. For further information on Fast Track Systems please visit our companywebsite: www.Fast-Track.com. About Celsion: Celsion Corporation, based in Columbia, Maryland, is a biotechnologycompany dedicated to the development and commercialization of heatactivated treatment systems for cancer. Celsion has research, license or commercialization agreements with leadinginstitutions such as the National Institute of Health, Duke UniversityMedical Center, Massachusetts Institute of Technology, Harbor UCLA MedicalCenter, Montefiore Medical Center and Memorial Sloan-Kettering CancerCenter in New York City, Roswell Park Cancer Institute in Buffalo, NewYork, and Duke University. For more information on Celsion, please visit our website: www.celsion.com. Frank CattieVP of SalesFast Track Systems, Inc.227 Washington Street, Suite 310Conshohocken, PA 19335Phone: 215-358-1400Fax: 215-283-1011Website: www.fast-track.comEmail: fcattie@fast-track.com SOURCE: Fast Track Systems, Inc.
Source: marketwire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|